BlinkLab (ASX:BB1) partnered with the US-based SHANK2 Foundation to support the expansion of its digital neurodiagnostic platform into neurodevelopmental disorders and rare disease research, according to a Friday filing with the Australian bourse.

The partnership gives the company access to a genetically defined patient population, allowing for the validation of its digital biomarkers in a biologically well-characterized neurodevelopmental disorder, the filing said.

The foundation is a non-profit organization focused on improving awareness and research infrastructure for rare neurodevelopmental conditions linked to mutations or deletions in the SHANK2 gene, per the filing.

BlinkLab shares rose 3% in midday trade on Friday.